TY - JOUR
T1 - Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant
AU - Sigmund, Audrey M.
AU - Zhao, Qiuhong
AU - Jiang, Justin
AU - Elder, Patrick
AU - Benson, Don M.
AU - Rosko, Ashley
AU - Bumma, Naresh
AU - Khan, Abdullah
AU - Devarakonda, Srinivas
AU - Vasu, Sumithira
AU - Jaglowski, Samantha
AU - Mims, Alice
AU - Choe, Hannah
AU - Larkin, Karilyn
AU - Brammer, Jonathan
AU - Wall, Sarah
AU - Grieselhuber, Nicole
AU - Saad, Ayman
AU - Penza, Sam
AU - Efebera, Yvonne A.
AU - Sharma, Nidhi
N1 - Publisher Copyright:
Copyright © 2022 Sigmund, Zhao, Jiang, Elder, Benson, Rosko, Bumma, Khan, Devarakonda, Vasu, Jaglowski, Mims, Choe, Larkin, Brammer, Wall, Grieselhuber, Saad, Penza, Efebera and Sharma.
PY - 2022/2/25
Y1 - 2022/2/25
N2 - Background: Allogeneic hematopoietic stem cell transplant (allo-HCT) is a potential curative therapy for a variety of hematologic disorders. However, it requires highly specialized care that is only available at select centers across the country. Thus, minority populations are at risk for healthcare disparities in access to and outcomes of allo-HCT. Our study aimed to assess the impact of race and location of residence on outcomes of allo-HCT. Methods: We performed a retrospective analysis of all patients who underwent allo-HCT at the Ohio State University from 1984 to 2018. Patients were divided by race (Caucasian, African American, and other) and grouped by zip code into rural, suburban, and urban groups. Primary endpoints included progression-free survival (PFS) and overall survival (OS). Results: Of the 1,943 patients included in the study, 94.3% self-identified as Caucasian, 4.6% African American, and 1.1% other. In total, 63.4% lived in rural areas, 22.9% suburban, and 13.8% urban. There was no significant difference in OS or PFS by race (p = 0.15, 0.21) or place of residence (p = 0.39, 0.17). In addition, no difference in nonrelapse mortality, acute and chronic graft-versus-host disease (GVHD), and GVHD-free relapse-free survival (GRFS) was seen among the race or place of residence. Conclusion: Our study suggests that when appropriate access to HCT is given, there is no difference in outcomes based on race, ethnicity or place of primary residence. Further research is needed to further evaluate barriers for these patients to undergo transplant and help mitigate these barriers.
AB - Background: Allogeneic hematopoietic stem cell transplant (allo-HCT) is a potential curative therapy for a variety of hematologic disorders. However, it requires highly specialized care that is only available at select centers across the country. Thus, minority populations are at risk for healthcare disparities in access to and outcomes of allo-HCT. Our study aimed to assess the impact of race and location of residence on outcomes of allo-HCT. Methods: We performed a retrospective analysis of all patients who underwent allo-HCT at the Ohio State University from 1984 to 2018. Patients were divided by race (Caucasian, African American, and other) and grouped by zip code into rural, suburban, and urban groups. Primary endpoints included progression-free survival (PFS) and overall survival (OS). Results: Of the 1,943 patients included in the study, 94.3% self-identified as Caucasian, 4.6% African American, and 1.1% other. In total, 63.4% lived in rural areas, 22.9% suburban, and 13.8% urban. There was no significant difference in OS or PFS by race (p = 0.15, 0.21) or place of residence (p = 0.39, 0.17). In addition, no difference in nonrelapse mortality, acute and chronic graft-versus-host disease (GVHD), and GVHD-free relapse-free survival (GRFS) was seen among the race or place of residence. Conclusion: Our study suggests that when appropriate access to HCT is given, there is no difference in outcomes based on race, ethnicity or place of primary residence. Further research is needed to further evaluate barriers for these patients to undergo transplant and help mitigate these barriers.
KW - GvHD
KW - allogeneic transplant
KW - geographic location of residence
KW - health disparities
KW - race
UR - https://www.scopus.com/pages/publications/85126180582
U2 - 10.3389/fonc.2022.801879
DO - 10.3389/fonc.2022.801879
M3 - Article
AN - SCOPUS:85126180582
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 801879
ER -